

United States Alzheimer'S Disease Therapeutics & Diagnostics Market Forecast 2022-2028

Market Report | 2022-06-21 | 150 pages | Inkwood Research

AVAILABLE LICENSES:

- Single User Price \$900.00
- Global Site License \$1000.00
- \$1200.00

Report description:

KEY FINDINGS

The United States Alzheimer's disease therapeutics & diagnostics market is estimated to progress with a 6.62% CAGR during the forecasting years 2022-2028. The market growth is driven by regular cognitive assessments of senior citizens and the easy availability of relevant drugs.

MARKET INSIGHTS

Alzheimer's is a degenerative disorder that attacks the neurons, affecting thinking, memory loss, behavioral changes, and language skills. The market is anticipated to grow, driven by the vast number of last-stage pipeline and disease-modifying drugs. The United States is the largest player in Alzheimer's disease diagnostics and therapeutics market. Besides, the country also has high expenditure on disease management and high detection rates in primary care settings. According to the US Census Bureau, the population of Americans aged 65+ is expected to surge to 88 million by 2050. These factors are expected to drive the market growth during the forecast years.

Furthermore, the United States Food and Drug Administration has approved various molecules to treat Alzheimer's disease. Also, a combination drug containing Memantine and Donepezil is widely available in the market. The availability of various drugs and molecules to cure the disease produces lucrative opportunities for medicine manufacturers.

COMPETITIVE INSIGHTS

Leading players in the market include GE Healthcare, Baxter International Inc, Amarantus Bioscience Holdings Inc, Cognoptix Inc, Merck & Co Inc, etc.

Our report offerings include:

- Explore key findings of the overall market
- Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
- Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
- Market Segmentation caters to a thorough assessment of key segments with their market estimations
- Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

- Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
- Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
- Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Table of Contents:

TABLE OF CONTENTS

- 1. RESEARCH SCOPE & METHODOLOGY
- 1.1. STUDY OBJECTIVES
- 1.2. SCOPE OF STUDY
- 1.3. METHODOLOGY
- 1.4. ASSUMPTIONS & LIMITATIONS
- 2. EXECUTIVE SUMMARY
- 2.1. MARKET SIZE & ESTIMATES
- 2.2. COUNTRY SNAPSHOT
- 2.3. COUNTRY ANALYSIS
- 2.4. KEY GROWTH ENABLERS
- 2.5. KEY CHALLENGES
- 3. KEY ANALYTICS
- 3.1. PARENT MARKET ANALYSIS
- 3.2. TIMELINE OF ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
- 3.3. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE
- 3.4. IMPACT OF COVID-19 ON ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
- 3.5. KEY MARKET TRENDS
- 3.6. PORTER'S FIVE FORCES ANALYSIS
- 3.6.1. BUYERS POWER
- 3.6.2. SUPPLIERS POWER
- 3.6.3. SUBSTITUTION
- 3.6.4. NEW ENTRANTS
- 3.6.5. INDUSTRY RIVALRY
- 3.7. KEY BUYING CRITERIA
- 3.8. SUPPLY CHAIN ANALYSIS
- 3.9. OPPORTUNITY MATRIX
- 3.10. PESTLE ANALYSIS UNITED STATES
- 4. MARKET BY THERAPEUTICS & DIAGNOSTICS
- 4.1. THERAPEUTICS
- 4.1.1. DRUGS
- 4.1.1.1. MARKETED DRUGS
- 4.1.1.2. PIPELINE DRUGS
- 4.1.2. DISEASE STAGE
- 4.1.2.1. LATE-STAGE: SEVERE AD
- 4.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD
- 4.1.2.3. PRODROMAL STAGE
- 4.1.3. GENERIC & BRANDED
- 4.1.3.1. BRANDED
- 4.1.3.2. GENERIC
- 4.2. DIAGNOSTICS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.2.1. LUMBAR PUNCTURE TEST
- 4.2.2. POSITRON EMISSION TOMOGRAPHY
- 4.2.3. ELECTROENCEPHALOGRAPHY
- 4.2.4. MAGNETIC RESONANCE IMAGING
- 4.2.5. COMPUTED TOMOGRAPHY
- 4.2.6. BLOOD TEST
- 4.2.7. OTHER DIAGNOSTICS
- 5. COMPETITIVE LANDSCAPE
- 5.1. KEY STRATEGIC DEVELOPMENTS
- 5.1.1. MERGERS & ACQUISITIONS
- 5.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 5.1.3. PARTNERSHIPS & AGREEMENTS
- 5.1.4. BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES
- 5.2. COMPANY PROFILES
- 5.2.1. AMARANTUS BIOSCIENCE HOLDINGS INC
- 5.2.2. BAXTER INTERNATIONAL INC
- 5.2.3. BIOGEN INC
- 5.2.4. COGNOPTIX INC
- 5.2.5. ELI LILLY & COMPANY
- 5.2.6. GE HEALTHCARE
- 5.2.7. JOHNSON & JOHNSON
- 5.2.8. MERCK & CO INC
- 5.2.9. PFIZER INC

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com



United States Alzheimer'S Disease Therapeutics & Diagnostics Market Forecast 2022-2028

Market Report | 2022-06-21 | 150 pages | Inkwood Research

To place an Order w	ith Scotts International:			
- Print this form				
☐ - Complete the re	elevant blank fields and sign			
Send as a scan	ned email to support@scotts-intern	ational.com		
ORDER FORM:				
Select license	License			Price
	Single User Price			\$900.00
	Global Site License			\$1000.00
				\$1200.00
			VAT	
			Total	
*Please circle the relev	ant license option. For any questions pla	ease contact support@:	scotts-international.com or 0048 603 3	94 346.
	rant license option. For any questions plo at 23% for Polish based companies, indiv			
** VAT will be added a		viduals and EU based co		
Email* First Name*		viduals and EU based co		
** VAT will be added a		viduals and EU based co		
Email* First Name*		viduals and EU based co	companies who are unable to provide a	
Email* First Name* Job title*		viduals and EU based co Phone* Last Name*	companies who are unable to provide a	
Email* First Name* Job title* Company Name*		Phone* Last Name* EU Vat / Tax ID /	companies who are unable to provide a	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com